Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

U.S. House Health Reform Bill Would Add Tens Of Millions To Health Coverage
Health reform legislation moving through the U.S. House of Representatives would reverse the continued and growing loss of health coverage by American families and would give millions of Americans the security of stable, quality, affordable coverage, according to a report released today by the consumer health organization Families USA.
generic viagra online
Spike In Australian H1N1 Cases Could Lead WHO To Declare Pandemic
The H1N1 (swine flu) outbreak could soon be declared the first flu pandemic in 41 years after a recent jump in the number of confirmed cases in Australia, WHO officials said Tuesday, the AP/Google.com reports (Jordans, AP/Google.com, 6/9).
News of the day
AccuVein Vein Illuminator Receives European CE Mark
AccuVein LLC, maker of the AV300, the world"s first hand-held, non-contact vein illumination device, announced today that its medical device now carries a CE Mark, enabling the Company to commence European sales of AccuVein"s AV300.
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323

UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec"s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009